Filing Flows › Anika Therapeutics (ANIK) › Q3 2026 › vs Q2 2026
Anika Therapeutics (ANIK) Q3 2026 vs Q2 2026 (quarter over quarter)
Anika Therapeutics's revenue fell $2.0M (-6%) from $32.6M in Q2 2026 to $30.6M in Q3 2026. The biggest changes: OEM Channel −$2.1M (-11%); Commercial Channel +$88K (+0.6%).
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 22.0% | -6.5% | +28.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| OEM Channel | $16.6M | $18.7M | −$2.1M | -11% |
| Commercial Channel | $14.0M | $13.9M | $88K | +0.6% |
| Revenue | $30.6M | $32.6M | −$2.0M | -6% |
| Other income, net | $390K | $426K | −$36K | -8% |
| Income tax benefit | $11K | −$71K | $82K | — |
| Net loss | $311K | −$3.3M | $3.6M | — |
| Costs & expenses | $31.3M | $33.0M | −$1.7M | -5% |
| Operating costs | $31.3M | $29.7M | $1.6M | +6% |
| Cost of revenue | $11.8M | $11.4M | $391K | +3% |
| Research & development | $7.9M | $7.3M | $554K | +8% |
| SG&A | $11.7M | $10.9M | $705K | +6% |
| Operating cash sources | $8.7M | −$4.0M | $12.7M | — |
| Depreciation & amortization | $1.4M | $1.5M | −$66K | -4% |
| Share-based compensation | $4.2M | $1.8M | $2.4M | +132% |
| Working capital & other | $3.0M | −$7.3M | $10.3M | — |
| Net loss absorbed | $311K | −$3.3M | $3.6M | — |
| Operating cash flow | $8.4M | −$684K | $9.1M | — |
| Free cash flow (OCF − capex) | $6.7M | −$2.1M | $8.8M | — |
| Capital expenditures | $1.7M | $1.4M | $212K | +15% |
Questions
How much did Anika Therapeutics's revenue grow quarter over quarter in Q3 2026?
Anika Therapeutics's revenue fell $2.0M (-6%) from $32.6M in Q2 2026 to $30.6M in Q3 2026.
What drove Anika Therapeutics's revenue change in Q3 2026?
OEM Channel −$2.1M (-11%); Commercial Channel +$88K (+0.6%).